Cargando…

Comparative analysis of enoxaparin versus rivaroxaban in the treatment of cancer associated venous thromboembolism: experience from a tertiary care cancer centre

BACKGROUND: Venous Thromboembolism (VTE) in cancer patients is associated with increased mortality and morbidity. While newer data on use of direct oral anticoagulants (DOACs) in treating cancer associated thrombosis (CAT) is promising; its data is still few and inconsistent across literature. We de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Faqah, Anadil, Sheikh, Hassan, Bakar, Muhammad Abu, Tayyaab, Fatima, Khawaja, Sahrish
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245926/ https://www.ncbi.nlm.nih.gov/pubmed/32489329 http://dx.doi.org/10.1186/s12959-020-00221-2

Ejemplares similares

Rivaroxaban versus enoxaparin for the prevention of recurrent venous thromboembolism in patients with cancer: A meta-analysis
por: Xing, Jiali, et al.
Publicado: (2018)

Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment
por: Bauersachs, Rupert M, et al.
Publicado: (2014)

Rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total knee arthroplasty: A meta-analysis
por: Huang, Hai-Feng, et al.
Publicado: (2018)

Cost-Effectiveness Rivaroxaban versus Enoxaparin for Prevention of Venous Thromboembolism after Knee Replacement Surgery in Iran
por: Abutorabi, Ali, et al.
Publicado: (2023)

Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After major Gynecological Cancer Surgery: The VALERIA Trial: Venous thromboembolism prophylAxis after gynecoLogical pElvic cancer surgery with RIvaroxaban versus enoxAparin (VALERIA trial)
por: Longo de Oliveira, André Luiz Malavasi, et al.
Publicado: (2022)

Benefit–risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty
por: Levitan, Bennett, et al.
Publicado: (2014)

Rivaroxaban for cancer-associated venous thromboembolism
por: Liang, Bo, et al.
Publicado: (2021)

Comparison of Enoxaparin and Rivaroxaban in the Prophylaxis of Deep Venous Thrombosis in Arthroplasty
por: Çiçek, Necati, et al.
Publicado: (2021)

Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study
por: Trujillo‐Santos, Javier, et al.
Publicado: (2022)

Comparison of the Efficacy and Safety of Aspirin and Rivaroxaban Following Enoxaparin Treatment for Prevention of Venous Thromboembolism after Hip Fracture Surgery
por: Huang, Qiang, et al.
Publicado: (2019)

Prevention of venous thromboembolism with enoxaparin in bariatirc surgery
por: Woo, Hee Doo, et al.
Publicado: (2013)

Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
por: Bauersachs, Rupert, et al.
Publicado: (2020)

Safety of Enoxaparin as Venous Thromboembolism Prophylaxis After Rhytidectomy
por: Lisiecki, Jeffrey L., et al.
Publicado: (2019)

Real-World Data (RWD) on the 3-Year Follow-Up Outcomes of Different CNS Prophylaxis Strategies Across CNS-IPI Risk Groups in Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma
por: Faqah, Anadil, et al.
Publicado: (2021)

Fatigue after initiating rivaroxaban for venous thromboembolism
por: Karlsvik, Tina Margrethe, et al.
Publicado: (2020)

Optimal Dosing of Enoxaparin in Critically Ill Patients with Venous Thromboembolism
por: Abdulla, Aliya, et al.
Publicado: (2023)

Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer
por: Lee, Jang Ho, et al.
Publicado: (2019)

Rivaroxaban in acute venous thromboembolism: UK prescribing experience
por: Speed, Victoria, et al.
Publicado: (2021)

Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding
por: Caroti, Kimberly Snow, et al.
Publicado: (2023)

Bemiparin versus Enoxaparin in the Prevention of Venous Thromboembolism among Intensive Care Unit Patients
por: Abbas, Mohamed Sayed
Publicado: (2017)

Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in Low Body Weight Patients
por: Dybdahl, Daniel, et al.
Publicado: (2019)

Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism
por: Harder, Sebastian
Publicado: (2014)

Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism
por: Coleman, Craig I., et al.
Publicado: (2018)

Biosimilar versus branded enoxaparin to prevent postoperative venous thromboembolism after surgery for digestive tract cancer: Randomized trial
por: Dziri, Chadli, et al.
Publicado: (2023)

Rivaroxaban for cancer-associated venous thromboembolism: A systematic review and meta-analysis protocol
por: Liang, Bo, et al.
Publicado: (2019)

Comparison of rivaroxaban and dalteparin for the long-term treatment of venous thromboembolism in patients with gynecologic cancers
por: Lee, Jang Ho, et al.
Publicado: (2019)

Rivaroxaban Efficacy and Safety in SELECT-D Community Cancer-Associated Venous Thromboembolism Patients
por: Carlin, Stephanie, et al.
Publicado: (2023)

Effectiveness and Safety of Rivaroxaban and Low Molecular Weight Heparin in Cancer-Associated Venous Thromboembolism
por: Coleman, Craig I., et al.
Publicado: (2023)

Rivaroxaban treatment of cancer‐associated venous thromboembolism: Memorial Sloan Kettering Cancer Center institutional experience
por: Soff, Gerald A., et al.
Publicado: (2019)

Oral Rivaroxaban Versus Standard Therapy in Acute Venous Thromboembolism Treatment for Vietnamese Patients
por: Bui, My Hanh, et al.
Publicado: (2019)

Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism
por: Bistervels, Ingrid M., et al.
Publicado: (2022)

The economic impact of enoxaparin versus unfractionated heparin for prevention of venous thromboembolism in acute ischemic stroke patients
por: Pineo, Graham F, et al.
Publicado: (2012)

Assessment of anti-factor Xa activity of enoxaparin for venous thromboembolism prophylaxis in morbidly obese surgical patients
por: Al Otaib, Nouf, et al.
Publicado: (2017)

Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism
por: Berger, Jeffrey S., et al.
Publicado: (2017)

Treatment with rivaroxaban and monitoring of coagulation profiles in two dogs with venous thromboembolism
por: UCHIDA, Mona, et al.
Publicado: (2020)

Adherence to rivaroxaban for the treatment of venous thromboembolism–Results from the FIRST registry
por: Speed, Victoria, et al.
Publicado: (2021)

Efficacy and Safety of Enoxaparin for Preventing Venous Thromboembolic Events following Urologic Laparoscopic Surgery
por: Nomura, Takeo, et al.
Publicado: (2013)

The use of enoxaparin as venous thromboembolism prophylaxis in bariatric surgery: A retrospective cohort study
por: Altawil, Esraa, et al.
Publicado: (2022)

742 Evaluation of Anti-Xa Levels and Venous Thromboembolism Prophylaxis with Enoxaparin in Burn Patients
por: Boyd, Allison, et al.
Publicado: (2023)

Clot regression effects of rivaroxaban in the treatment of venous thromboembolism in patients with cancer (CRERIT-VTE cancer): study protocol
por: Takai, Shigeki, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_k1ge1a533hegdc7g2au9dqph0u